FRX vs. CRON, TEV, ABT, SLS, NOT, PYR, NVO, DNA, TLRY, and VBV
Should you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include Cronos Group (CRON), Tervita (TEV), Absolute Software Co. (ABT.TO) (ABT), Solaris Resources (SLS), Noront Resources (NOT), PyroGenesis Canada Inc. (PYR.V) (PYR), Novo Resources Corp. (NVO.V) (NVO), Dalradian Resources (DNA), Tilray Brands (TLRY), and VBI Vaccines (VBV). These companies are all part of the "pharmaceutical products" industry.
Fennec Pharmaceuticals vs.
Cronos Group (TSE:CRON) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, community ranking, dividends, media sentiment and analyst recommendations.
In the previous week, Fennec Pharmaceuticals had 14 more articles in the media than Cronos Group. MarketBeat recorded 14 mentions for Fennec Pharmaceuticals and 0 mentions for Cronos Group. Fennec Pharmaceuticals' average media sentiment score of 0.84 beat Cronos Group's score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the news media.
Fennec Pharmaceuticals has lower revenue, but higher earnings than Cronos Group. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.
Fennec Pharmaceuticals received 35 more outperform votes than Cronos Group when rated by MarketBeat users. Likewise, 69.80% of users gave Fennec Pharmaceuticals an outperform vote while only 50.74% of users gave Cronos Group an outperform vote.
16.0% of Cronos Group shares are held by institutional investors. Comparatively, 52.8% of Fennec Pharmaceuticals shares are held by institutional investors. 46.4% of Cronos Group shares are held by insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Fennec Pharmaceuticals has a net margin of -2.30% compared to Cronos Group's net margin of -42.65%. Fennec Pharmaceuticals' return on equity of 29.94% beat Cronos Group's return on equity.
Cronos Group has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500.
Summary
Fennec Pharmaceuticals beats Cronos Group on 12 of the 17 factors compared between the two stocks.
Get Fennec Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FRX and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fennec Pharmaceuticals Competitors List
Related Companies and Tools
This page (TSE:FRX) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy FRX Stock Free FRX Stock Alerts